The Globe and Mail reports in its Thursday edition that Brookfield Asset Management has pulled its 6.45-billion-euro ($9.5-billion (Canadian)) offer to take Spanish drug maker Grifols SA private after failing to agree on the purchase price. The Globe's James Bradshaw writes that the private equity arm of Brookfield joined the founding family behind Grifols to table a non-binding joint proposal to the Grifols board earlier in November, after months of negotiations. The proposal and its tentative offer price was publicly disclosed on Nov. 19, but Grifols resisted the takeover, saying the offer significantly undervalued the company. The deadlock over the offer price came after months of talks and work to raise financing for a deal, and in spite of support from the Grifols family, which owns nearly 30 per cent of the multinational pharmaceutical company's shares. Grifols specializes in producing blood-plasma-based products, which are part of life-saving medicines used to treat people with compromised immune systems from cancer treatment, autoimmune disorders or other reasons. Its push into Canada has included a controversial partnership with Canadian Blood Services to pay plasma donors. Brookfield could still make a new bid.